Brain Scientific Inc.

Brain Scientific Inc., a medtech company, provides neurology-focused medical devices and electric motors in the United States. The company also develops motor platforms; an ultra-precise micro dosing pump; and motion products. The company offers NeuroCap, a disposable and soft layered cap with an integrated electrode circuit that is designed to address existing problems of conventional EEG systems; and NeuroEEG, a clinical-grade device for prescription use to acquire, record, transmit, and display electrical brain activity for patients of all ages, as well as NeuroNet Cloud, a database where brain data can be stored and analyzed. Brain Scientific Inc. was founded in 2013 and is headquartered in Sarasota, Florida.

Brain Scientific Inc. trades as BRSF on OTC. The company is classified in Healthcare / Medical - Devices and reports in USD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $214,564 of revenue and -$12.34M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Brain Scientific Inc. can be compared against peers such as American Oriental Bioengineering, Inc., Aspyra Inc., Clever Leaves Holdings Inc., Enchanted World Inc., Cue Health Inc., HTG Molecular Diagnostics, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $746, beta of 1.59, and return on equity of -285.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BRSF currently shows total debt of $2.86M and beta of 1.59. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.brainscientific.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.